Chest
Clinical InvestigationsMiscellaneousTwo Studies of the Clinical Effectiveness of the Nicotine Patch With Different Counseling Treatments
Section snippets
Methods
Two studies were conducted sequentially to assess the efficacy of nicotine patch therapy with different adjuvant counseling approaches. Subjects were recruited independently for the two studies, and were unaware of the type of adjuvant treatment to be used. In study 1, patch therapy was paired with group counseling. In study 2, the nicotine patch was paired with brief individual counseling. The methods used in both studies were similar except as noted below.
Study 1
Table 1 depicts the baseline characteristics of subjects in the active and placebo groups. No statistically significant differences between the two groups were obtained. Of the 88 subjects who were enrolled and randomized, 77 completed the cessation treatment phase (ie, wore patches as directed for 8 weeks) of the study. Of the 11 who failed to complete the cessation treatment phase (first 8 weeks on study), 10 had placebo patches and 1 had active treatment.
Efficacy
End of Treatment: At the end of patch
Discussion
Along with a growing body of research,6,8, 9, 10, 11, 12,20, 21, 22 these studies show that the nicotine patch is very effective in increasing the rates of both short-term and long-term smoking abstinence among individuals motivated to quit. In both study 1 and 2, point prevalence and survival analyses demonstrated that patients wearing the nicotine patch were more successful in quitting smoking. Moreover, this research adds to the literature by demonstrating that the nicotine patch is
References (24)
- et al.
Meta-analysis of randomised controlled trials of nicotine chewing-gum
Lancet
(1987) - et al.
Controlled trial of transdermal nicotine patch in tobacco withdrawal
Lancet
(1989) - et al.
Nicotinereplacement therapy with use of a transdermal nicotine patch—a randomized double-blind placebo-controlled trial
Mayo Clin Proc
(1990) - et al.
Optimizing nicotine-dependence treatment: a role for inpatient programs
Mayo Clin Proc
(1992) - et al.
Quitting smoking in the United States in 1986
J Natl Cancer Inst
(1990) Smoking-attributable mortality and years of potential life lost: United States, 1988
MMWR
(1991)Smoking: human and economic costs
Cancer Invest
(1989)- et al.
Signs and symptoms of tobacco withdrawal
Arch Gen Psychiatry
(1986) - et al.
The tobacco withdrawal syndrome in unaided quitters
Br J Addict
(1991) - et al.
Tobacco dependence and the nicotine patch: clinical guidelines for effective use
JAMA
(1992)
Clinical and pharmacokinetic properties of a transdermal nicotine patch
Clin Pharmacol Ther
Effectiveness of a transdermal nicotine system in smoking cessation studies
Methods Find Exp Clin Pharmacol
Cited by (117)
Help me quit smoking but don't make me sick! The controversial effects of electronic cigarettes on tobacco smokers
2021, Social Science and MedicineElectronic cigarettes as a smoking-cessation tool: Results from an online survey
2011, American Journal of Preventive MedicineCitation Excerpt :However, even with the assistance of medications that treat nicotine addiction, the success rate for quitting remains low. Based on a Cochrane review of seven studies4–9 that measured smoking cessation using nicotine replacement therapy (NRT), the average 6-month point prevalence of smoking abstinence is only 17.8%, and the 6-month point prevalence of smoking abstinence in the pooled data from these studies is only 11.9%. Several studies10,11 have suggested that physical and behavioral stimuli—such as merely holding a cigarette—can reduce the craving to smoke, even in the absence of nicotine delivery.
Smoking-induced change in intrasynaptic dopamine concentration: Effect of treatment for Tobacco Dependence
2010, Psychiatry Research - NeuroimagingCitation Excerpt :Results of the clinical treatment portion of the study demonstrated the expected decreases in smoking measures (FTND scores, reported numbers of cigarettes per day, and exhaled CO levels) for all treatments, with more robust findings in the actively-treated than the placebo-treated groups (Table 1). These findings were consistent with prior research examining the effects of bupropion HCl treatment on smoking measures (Fiore et al., 1994; Hurt et al., 1997). In addition, the entire sample (3 subgroups combined) had lower total puff volumes of the cigarette smoked during the follow-up PET session, and this effect was strongest in the bupropion-treated group (Table 1).
Smoking cessation
2009, Asthma and COPDSmoking cessation
2008, Asthma and COPD: Basic Mechanisms and Clinical ManagementAddictive consumption of psychoactive substances
2007, Medicine
This study was supported by a research grant provided by Elan Pharmaceutical Research Corporation, Gainesville, Ga, and Athlone, Ireland.
revision accepted June 30.